Efficacy of early immunomodulator therapy on the outcomes of Crohn's disease

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Kwak, Min S ^a   Kim, Duk H ^a   Park, Soo J ^a   Kim, Tae I ^a   Hong, Sung P ^a   Kim, Won H ^a   Cheon, Jae H ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

6 mercaptopurine; Azathioprine; Crohn's disease; Immunomodulator

Indexed keywords

C REACTIVE PROTEIN; IMMUNOMODULATING AGENT; AZATHIOPRINE; CORTICOSTEROID; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE;

ABDOMINAL PAIN; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL INDICATOR; CONTROLLED STUDY; CROHN DISEASE; DERMATITIS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EARLY INTERVENTION; EDEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PROGNOSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SOUTH KOREA; UNSPECIFIED SIDE EFFECT; ADOLESCENT; COHORT ANALYSIS; IMMUNOLOGY; KAPLAN MEIER METHOD; STATISTICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

6-MERCAPTOPURINE; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AZATHIOPRINE; C-REACTIVE PROTEIN; COHORT STUDIES; CROHN DISEASE; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84900022970     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-85     Document Type: Article

References (26)

1. Ling KL, Chuah SW, Kong SC. Healing the mucosa in Crohn's disease: does it matter?. Singap Med J 2013, 54(4):185-189.
2. Fascì Spurio F, Aratari A, Margagnoni G, Doddato MT, Papi C. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid?. J Gastrointestin Liver Dis 2012, 21(1):67-73.
3. Eugene C. The second European evidence-based consensus on the diagnosis and management of Crohn's disease (part 4). Clin Res Hepatol Gastroenterol 2011, 35(8-9):518-520.
4. Cosnes J, Nion Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54(2):237-241. 10.1136/gut.2004.045294, 1774826, 15647188.
5. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D, . Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (London, England) 2008, 371(9613):660-667. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club.
6. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50(4):485-489. 10.1136/gut.50.4.485, 1773162, 11889067.
7. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989, 170:2-6.
8. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979, 77(4):843-846.
9. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, Travis S, Stange E, . European Crohn's and Colitis Organisation (ECCO) The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010, 4(1):7-27. 10.1016/j.crohns.2009.12.003, 21122488, European Crohn's and Colitis Organisation (ECCO).
10. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995, 30(7):699-706. 10.3109/00365529509096316, 7481535.
11. Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical prognostic factors for disabling Crohn's disease: a systematic review and meta-analysis. World J Gastroenterol 2013, 19(24):3866-3871. 10.3748/wjg.v19.i24.3866, 3699033, 23840127.
12. Kirwan JR. Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J Rheumatol 1999, 26(3):720-725.
13. Punati J, Markowitz J, Lerer T, Hyams J, Kugathasan S, Griffiths A, Otley A, Rosh J, Pfefferkorn M, Mack D, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Mezoff A, Leleiko N, Keljo D, Crandall W, . Pediatric IBD Collaborative Research Group Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis 2008, 14(7):949-954. 10.1002/ibd.20412, 18306311, Pediatric IBD Collaborative Research Group.
14. Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas J-L, Reimund J-M, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF, . Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID) Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial. Gastroenterology 2013, 145(4):758-765. 10.1053/j.gastro.2013.04.048, 23644079, Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID).
15. Panés J, López-SanRomán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, Domènech E, Piqueras M, Gomez-García M, Gutiérrez A, Taxonera C, Sans M, . AZTEC Study Group Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013, 145(4):766-774. 10.1053/j.gastro.2013.06.009, 23770132, AZTEC Study Group.
16. Wolters FL, Russel MG, Stockbrügger RW. Systematic review: has disease outcome in Crohn's disease changed during the last four decades?. Aliment Pharmacol Ther 2004, 20(5):483-496. 10.1111/j.1365-2036.2004.02123.x, 15339320.
17. Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp J, Lakatos L. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol 2009, 15(28):3504-3510. 10.3748/wjg.15.3504, 2715976, 19630105.
18. Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver 2010, 4(1):1-14. 10.5009/gnl.2010.4.1.1, 2871616, 20479907.
19. Sans M, López-San Román A, Esteve M, Bermejo F, García-Sánchez V, Torres Y, Domenech E, Piqueras M, Aceituno M, Gomez-Garcia M, Taxonera C, Gisbert JP. Early use of azathioprine Has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology 2011, 140(5):S-109.
20. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007, 25(3):247-255.
21. Reinisch W, Wang Y, Oddens BJ, Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012, 35(5):568-576. 10.1111/j.1365-2036.2011.04987.x, 22251435.
22. Consigny Y, Modigliani R, Colombel J, Dupas J, Lémann M, Mary J. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006, 12(7):551-557. 10.1097/01.ibd.0000225334.60990.5b, 16804391.
23. Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008, 14(1):85-89. 10.3748/wjg.14.85, 2673397, 18176967.
24. Bitton A, Dobkin PL, Edwardes MD, Sewitch MJ, Meddings JB, Rawal S, Cohen A, Vermeire S, Dufresne L, Franchimont D, Wild GE. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 2008, 57(10):1386-1392. 10.1136/gut.2007.134817, 18390994.
25. Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis 2010, 11(3):134-147. 10.1111/j.1751-2980.2010.00429.x, 20579217.
26. Ye BD, Yang S, Cho YK, Park SH, Yang D, Yoon SM, Kim KJ, Byeon J, Myung S, Yu CS, Kim JH. Clinical features and long-term prognosis of Crohn's disease in Korea. Scand J Gastroenterol 2010, 45(10):1178-1185. 10.3109/00365521.2010.497936, 20560811.